Cyriac Roeding is the CEO of Earli, a gene therapy company aiming to make cancer a manageable condition by forcing tumors to express synthetic, non-human biomarkers for early detection.
A successful founder and investor, Cyriac previously served as CEO of Shopkick, acquired for $250M, and has invested in breakthrough companies like OpenAI. He’s known for building ventures at the intersection of the physical and digital worlds. Now leading Earli, he’s raised nearly $60M from top-tier investors to advance the company’s mission and redefine how cancer is detected and treated.
Get the latest from The Biotech Startups Podcast delivered straight to your inbox. Subscribe for weekly updates on new episode.
